A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma-MedSci.cn

A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

Spencer, A; Rosenberg, AS; Jakubowiak, A; Raje, N; Chatterjee, M; Trudel, S; Bahlis, NJ; Siegel, DS; Wilop, S; Harrison, SJ; NagaKrishna, M; Dhuria, S; Hindoyan, A; McIver, Z; Henary, H; Morrow, PK; Roberts, A

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019; 19 (10): E53

科室
- - 订阅+
  - 更多科室
工具
服务